Jeffrey Topal, MD
DownloadHi-Res Photo
Cards
Titles
Clinical Instructor
Contact Info
About
Titles
Associate Clinical Professor of Medicine (Infectious Diseases)
Clinical InstructorAppointments
Infectious Diseases
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Yale School of Medicine (1999)
- Resident
- Hospital of the University of Pennsylvania (1994)
- MD
- Tufts University (1991)
- BA
- University of Pennsylvania (1987)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jeffrey Topal's published research.
Publications Timeline
A big-picture view of Jeffrey Topal's research output by year.
Marwan Mikheal Azar, MD, FAST, FIDSA
Paul Albert Trubin, MD
4Publications
1Citations
Publications
2024
Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah S, Clarke L, Davis M, Topal J, Shields R. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal Of Antimicrobial Chemotherapy 2024, dkae205. PMID: 38958234, DOI: 10.1093/jac/dkae205.Peer-Reviewed Original ResearchAltmetricConceptsPseudomonas endocarditisFirst-lineClinical outcomesShorter time to treatment initiationFactors associated with treatment failureInvestigate clinical outcomes of patientsClinical outcomes of patientsTime to treatment initiationRate of adverse effectsProsthetic valve endocarditisFirst-line therapyOrgan transplant recipientsOutcomes of patientsInvestigate clinical outcomesIntracardiac complicationsDuke criteriaMicrobiological failureDrug discontinuationValve endocarditisCombination therapyTreatment failureTransplant recipientsDay mortalityInitial treatmentClinical benefitNocardiosis in Kidney Transplant Recipients and Possible Association With Decreased Utilization of Trimethoprim/Sulfamethoxazole During COVID-19
Marvin J, McSweeney T, Cohen E, Davis M, Belfield K, Do V, Virmani S, McManus D, Tirmizi S, Topal J. Nocardiosis in Kidney Transplant Recipients and Possible Association With Decreased Utilization of Trimethoprim/Sulfamethoxazole During COVID-19. Transplantation 2024, 108: e150-e151. PMID: 38917242, DOI: 10.1097/tp.0000000000004974.Peer-Reviewed Original ResearchAltmetricClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients
2023
2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
Perreault S, Schiffer M, Roeder H, McManus D, Topal J. 2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed? Open Forum Infectious Diseases 2023, 10: ofad500.2348. PMCID: PMC10678736, DOI: 10.1093/ofid/ofad500.2348.Peer-Reviewed Original ResearchConceptsInvasive fungal infectionsBreakthrough invasive fungal infectionsAntifungal prophylaxisFluconazole prophylaxisRisk factorsDay 75Conditioning regimenRisk patientsLower incidenceAllogeneic hematopoietic stem cell transplant patientsHistory of IFIRate of IFIHematopoietic stem cell transplant patientsHigh-intensity conditioning regimensStem cell transplant patientsFungal infectionsAnti-mold prophylaxisHigh-dose steroidsRoutine antifungal prophylaxisTacrolimus/sirolimusIntensity conditioning regimensHigh-risk patientsLow-risk patientsCell transplant patientsBreakthrough fungal infections
Clinical Care
Overview
Clinical Specialties
Internal Medicine; Infectious Diseases
Fact Sheets
Pneumonia
Learn More on Yale MedicineCOVID-19
Learn More on Yale MedicineCoronavirus
Learn More on Yale MedicineParasitic Diseases
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- June 05, 2023
Discoveries & Impact (June 2023)
- September 20, 2022
Ad Hoc Treatment Team Develops COVID Guidelines
- April 25, 2022Source: Yale Medicine
12 Things To Know About Paxlovid, the Latest COVID-19 Pill
- July 15, 2021
Congratulations to Quality & Safety Process Improvement Grant Winners
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.